How Artificial Intelligence Is Changing Scientific Research

Context: the year AI's role in science got a Nobel Prize

For years, claims about AI transforming science ran ahead of the evidence. That changed decisively in October 2024, when the Nobel Prize in Chemistry was awarded partly for AlphaFold — an AI system that solved a fundamental biological problem researchers had wrestled with for half a century. The Nobel committee's recognition marked a shift from AI-in-science as promise to AI-in-science as demonstrated, prize-winning fact, and it is worth understanding both what that breakthrough actually did and where the broader hype still outruns reality.

The data: what AlphaFold changed, in numbers

The problem AlphaFold solved is called protein folding. Proteins are chains of amino acids that fold into intricate three-dimensional shapes, and that shape determines what the protein does — which means understanding structure is the gateway to understanding biology and designing drugs. Experimentally determining a single protein's structure, using techniques like X-ray crystallography, could take months or years. AlphaFold, developed by Google DeepMind, predicts the structure from the amino acid sequence in hours, with accuracy rivalling experimental methods for a large share of proteins.

The scale of what followed is the headline. The AlphaFold Protein Structure Database, run jointly with the European Bioinformatics Institute, now holds over 200 million predicted structures — covering nearly every protein in major sequence databases. Before AlphaFold, science had experimentally determined structures for only a small fraction of known proteins. In October 2024, DeepMind's Demis Hassabis and John Jumper shared the Nobel Prize in Chemistry for the achievement, alongside David Baker, recognised for the related field of computational protein design.

What's changing: from prediction to discovery, unevenly

AlphaFold is the flagship, but AI is now embedded across the research pipeline. In drug discovery, models screen enormous chemical libraries, predict how candidate molecules will bind to disease targets, and design new compounds far faster than traditional trial-and-error. Several AI-designed or AI-optimised drug candidates have entered clinical trials. In climate science, machine-learning weather and climate models now rival traditional physics-based simulations for certain forecasting tasks at a fraction of the computing cost. In materials science, AI has proposed vast numbers of candidate stable materials for experimental testing.

But the acceleration is uneven, and the caveats matter. No fully AI-discovered drug has yet completed the entire approval process — the hardest, most expensive stage, proving safety and efficacy in humans, remains stubbornly resistant to shortcuts. And the research community has grown increasingly vocal about the risks that come with the gains.

"AlphaFold is a genuine scientific revolution. But a lot of what gets marketed as 'AI is doing science' is really AI is doing a narrow, well-defined prediction task extremely well — which is enormously valuable, but not the same as AI understanding or explaining the science." — a distinction widely echoed in the scientific literature, including commentary in Nature on where AI genuinely advances research.

What it means for you (and for science's reliability)

For anyone who relies on scientific progress — which is everyone — the practical upside is faster movement on hard problems: drug candidates identified sooner, disease mechanisms mapped faster, materials for clean energy proposed at scale. But there are risks worth understanding. Reproducibility is a growing concern: AI results can be hard for other researchers to replicate when training data or model details are not fully shared. "AI slop" — low-quality or fabricated AI-generated content, including text and images, appearing in published papers — is polluting parts of the research literature. And the explanation gap is a genuine tension: many AI models predict accurately without revealing why, which can advance capability without advancing the understanding that is science's actual purpose. These are being addressed through new reproducibility standards and disclosure requirements, but unevenly. For the human-trials side of the story, our explainer on how clinical trials work covers the stage AI has not yet been able to shortcut.

It is also worth being clear-eyed about what AI does not change. Science's core method — forming a hypothesis, testing it against reality, and requiring that others can reproduce the result — is not something AI replaces. AI can propose candidate structures, molecules or materials at a scale no human team could match, but each still has to be validated experimentally in the physical world, and that validation remains slow, expensive and essential. The risk is that the sheer speed and volume of AI-generated predictions outpaces the capacity to verify them, flooding the literature with plausible-looking results that have not been experimentally confirmed. The most careful researchers treat AI as a powerful hypothesis-generator that expands what is worth testing, not as a source of settled answers — a distinction that matters enormously for keeping the acceleration trustworthy rather than merely fast.

What to watch next

Watch whether an AI-discovered drug completes the full clinical approval process — a milestone that would move the drug-discovery story from "faster candidates" to genuinely validated end-to-end results, and which several companies are racing toward. Watch how the research community responds to reproducibility and AI-slop concerns, since science's credibility depends on results that others can verify. And watch the next generation of AlphaFold-style breakthroughs in adjacent fields — protein design, materials discovery, and mathematics, where AI systems have begun contributing to genuine research problems. For a related frontier where AI and physics intersect, see our coverage of progress in nuclear fusion, another field where computational modelling is accelerating experimental work.